medigraphic.com
ISSN 3061-8142 (Digital)
ISSN 0484-7903 (Impreso)

2011, Número 1

<< Anterior Siguiente >>

Rev Mex Anest 2011; 34 (1)


Impacto de las estatinas en el periodo perioperatorio

Carrillo-Esper R, Sosa-García JO

Idioma: Español
Referencias bibliográficas: 37
Paginas: 31-36
Archivo PDF: 315.21 Kb.


RESUMEN

Los eventos cardiovasculares son la principal complicación en el periodo perioperatorio. Las estatinas son el fármaco de elección en la prevención primaria y secundaria de patologías a nivel cardiovascular por su efecto hipolipemiante; sin embargo, sus beneficios van más allá debido a sus efectos pleiotrópicos en la modulación de la tríada patológica entre inflamación, obstrucción dinámica y trombosis en el perioperatorio. Estos efectos se han demostrado en estudios clínicos realizados en cirugía vascular no cardiaca, cirugía no cardiaca mayor, cirugía cardiovascular y cirugía cardiaca, reduciendo la incidencia de complicaciones. En conclusión, la implementación de la terapia con estatinas en el periodo perioperatorio reduce de manera significativa la morbimortalidad a corto y mediano plazo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Hall MJ, Owings MF. 2000 National Hospital Discharge Survey: Advance data from vital and health statistics, No. 329. Hyattsville, Md: National Center for Health Statistics 2002.

  2. Mangano DT. Perioperative cardiac morbidity. Anesthesiology 1990;72:153-184.

  3. Lee TH, Marcantonio ER, Mangione C, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999;100:1043-1049.

  4. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl J Med 1999;341:1789-1794.

  5. Nettleman MD, Banitt L, Barry W, Awan I, Gordon EEI. Predictors of survival and the role of gender in postoperative myocardial infarction. Am J Med 1997;103:357-362.

  6. Lindenauer PK, Fitzgerald J, Hoople N, Benjamin EM. The potential preventability of postoperative myocardial infarction: Underuse of perioperative B-adrenergic blockade. Arch Intern Med 2004;164:762-766.

  7. Yannick LM, Coriat P, Collard CD, Riedel B. Statin therapy within the perioperative period. Anesthesiology 2008;108:1141-1146.

  8. Chan YC, Cheng SW, Irwin MG. Perioperative use of statins in noncardiac surgery. Vascular Health and Risk Management 2008;4:75-81.

  9. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot 1876;29:1346-1348.

  10. Alberts AW, Chen J, Kuron G, et al. Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl- coenzyme. A reductase and a cholesterol-lowering agent. Proc Nat Acad Sci 1980;77:3957-3961.

  11. Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005;46:1425–1433.

  12. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207–213.

  13. Palinski W, Tsimikas S. Immunomodulatory effects of statins: Mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol 2002;13:1673–1681.

  14. Brookes ZL, McGown CC, Reilly CS. Statins for all: The new premed Br J Anaesth 2009;103:99-107.

  15. Fleisher LE, Beckman JA, Brown KA. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. Circulation 2007;116:e418–500.

  16. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–239.

  17. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 2003; 107:1848–51.

  18. Kertai MD, Boersma E, Westerhout CM, et al. A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery. Eur J Vasc Endovasc Surg 2004;28:343–352.

  19. Ward RP, Leeper NJ, Kirkpatrick JN, et al. The effect of preoperative statin therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. Int J Cardiol 2005;104:264–268.

  20. O’Neil-Callahan K, Katsimaglis G, Tepper MR, et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: The Statins for Risk Reduction in Surgery (StaRRS) study. J Am Coll Cardiol 2005;45:336–342.

  21. Durazzo AE, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: A randomized trial. J Vasc Surg 2004;39:967–976.

  22. Schouten O, Kertai MD, Bax JJ. Safety of perioperative statin use in high-risk patients undergoing major vascular surgery. Am J Cardiology 2005;95:658–660.

  23. Lindenauer PK, Pekow P, Wang K, Gutierrez B, Benjamin EM. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 2004;291:2092–9.

  24. Hindler K, Shaw AD, Samuels J, et al. Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology 2006;105:1260–1272.

  25. Ward S, Lloyd Jones M, Pandor A. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11:1–178.

  26. Kennedy J, Quan H, Buchan AM, Ghali WA, Feasby TE. Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients. Stroke 2005;36:2072–2076.

  27. McGirt MJ, Perler BA, Brooke BS, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy. J Vasc Surg 2005; 42:829–836.

  28. Liakopoulos OJ, Dorge H, Schmitto JD, et al. Effects of preoperative statin therapy on cytokines after cardiac surgery. Thorac Cardiovasc Surg 2006;54:250–254.

  29. Christenson JT. Preoperative lipid-control with simvastatin reduces the risk of postoperative thrombocytosis and thrombotic complications following CABG. Eur J Cardiothorac Surg 1999;15:394–399.

  30. Noordzij PG, Poldermans D, Schouten O. Beta-blockers and statins are individually associated with reduced mortality in patients undergoing noncardiac, nonvascular surgery. Coron Artery Dis 2007;8:67–72.

  31. Le Manach Y, Godet G, Coriat P. The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesth Analg 2007;104:1326–1333.

  32. Badner NH, Knill RL, Brown JE. Myocardial infarction after noncardiac surgery. Anesthesiology 1998;88:572–578.

  33. Feldman LS, Brotman DJ. Perioperative statins: More than lipid-lowering Cleveland Clinic Journal of Medicine 2008;75:654-662.

  34. Sethi M, Collard C. Perioperative statin therapy: Are formal guidelines and physician education needed. Anesth Analg 2007;104:1322–1324.

  35. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005;366:1267–1278.

  36. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495–1504.

  37. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001;285:1711–1718.




2020     |     www.medigraphic.com